• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 4, 2013

View Archived Issues

BioWorld Stock Index 2013

Read More

BioWorld Stock Report For Public Biotechnology Companies

Read More

Public Financing Of Biotechnology: October 2013

Read More

Other Financings Of Public Biotechnology Companies: October 2013

Read More

Nasdaq Stock Index 2013

Read More

Biotech Money Raised By Month In 2013

Read More

Top Private Financings Of Public Companies: 2013

Read More

Venture Capital And Other Investments In Private Biotechnology Companies: October 2013

Read More

Top Financings Of Private Companies: 2013

Read More

Milestone Payments From Corporate Partners: October 2013

Read More

Oral Therapies Seize the Spotlight in MS

Stellar third quarter earnings reported last week by Biogen Idec Inc., including another home run for the company with Tecfidera (dimethyl fumarate), put a spotlight on the promising pipeline of next-generation multiple sclerosis (MS) drugs. Weston, Mass.-based Biogen is smack in the middle of that hunt. In addition to its four commercial MS products – Ampyra/Fampyra (dalfampridine), Avonex (interferon beta-1a), Tysabri (natalizumab) and Tecfidera – the company has two MS drugs in Phase III development: Plegridy (peginterferon beta-1a) and anti-IL2 antibody daclizumab, which is partnered with Abbvie Inc., of Chicago. Read More

Start Reimbursement Planning Now for Regenerative Medicine

Companies need to start planning for reimbursement from Medicare and private insurances well ahead of FDA approval according to a new guide to reimbursement put out by the Alliance for Regenerative Medicine. Read More

Money Raised By Biotech Jan. 1 - Oct. 3, 2013

Read More

Good Financials Fail to Lift Biotech Sector in October

Biotech bubbleologists will be out in force following a rough month for the sector, which saw blue-chip companies developing new medicines collectively record their first reversal for over 18 months. Read More

Week in Review

Read More

Money Raised By Biotech In 2013 vs. 2012

Read More

Word on the Street

Read More

The Week's Biggest Gainers And Losers

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 26, 2025.
  • Deal handshake with coin, chart background

    After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept

    BioWorld
    Just a month after laying off 147 employees and announcing plans to mull “strategic alternatives,” Vor Biopharma Inc. reported raising $175 million in private...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • Lei Qian, clinical vice president, Innovent

    Innovent raises HKD$4.3B to advance R&D pipeline, global expansion

    BioWorld
    Innovent Biologics Inc. announced a HKD$4.3 billion (US$547 million) placement on the Hong Kong Stock Exchange to advance its R&D projects and to fund its global...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe